Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Janssen EJH, Bastiaans DET, Välitalo PAJ, van Rossum AMC, Jacqz-Aigrain E, Lyall H, Knibbe CAJ, Burger DM.

Br J Clin Pharmacol. 2017 Jun;83(6):1287-1297. doi: 10.1111/bcp.13227. Epub 2017 Feb 14.

PMID:
28079918
2.

Genotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone Marrow.

Moraes Filho AV, Carvalho CJ, Carneiro CC, Vale CR, Lima DC, Carvalho WF, Vieira TB, Silva DM, Cunha KS, Chen-Chen L.

PLoS One. 2016 Nov 2;11(11):e0165706. doi: 10.1371/journal.pone.0165706. eCollection 2016.

3.

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

Lahiri CD, Tao S, Jiang Y, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava A, Sanford S, Ofotokun I.

AIDS. 2015 Jun 1;29(9):1113-5. doi: 10.1097/QAD.0000000000000659.

4.

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.

Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ.

J Antimicrob Chemother. 2015 Jul;70(7):1928-41. doi: 10.1093/jac/dkv080. Epub 2015 Apr 8. Review.

5.

Neurotoxic effects of AZT on developing and adult neurogenesis.

Demir M, Laywell ED.

Front Neurosci. 2015 Mar 20;9:93. doi: 10.3389/fnins.2015.00093. eCollection 2015.

6.

HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, Shah R, MacGillivray J, Silverman M, Serghides L.

J Infect Dis. 2015 Jan 1;211(1):10-8. doi: 10.1093/infdis/jiu393. Epub 2014 Jul 16.

7.

Caring for women living with HIV: gaps in the evidence.

Loutfy MR, Sherr L, Sonnenberg-Schwan U, Walmsley SL, Johnson M, d'Arminio Monforte A; Women for Positive Action.

J Int AIDS Soc. 2013 Oct 1;16:18509. doi: 10.7448/IAS.16.1.18509. Review.

8.

Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, Goede M, Date AA, Destache CJ.

AIDS Res Hum Retroviruses. 2013 May;29(5):746-54. doi: 10.1089/AID.2012.0301. Epub 2013 Feb 1. Erratum in: AIDS Res Hum Retroviruses. 2013 Jul;29(7):1095. Date, Abjijit A [corrected to Date, Abhijit A].

9.

Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.

Klein SL.

Bioessays. 2012 Dec;34(12):1050-9. doi: 10.1002/bies.201200099. Epub 2012 Sep 26.

10.

Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.

Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3011-9. doi: 10.1128/AAC.06337-11. Epub 2012 Mar 5.

11.

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J, Gedela K, Abongomera G, Gazzard B, Boffito M.

Antivir Ther. 2012;17(1):19-24. doi: 10.3851/IMP1910.

12.

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.

Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19.

13.

Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi.

Taylor-Smith K, Tweya H, Harries A, Schoutene E, Jahn A.

Malawi Med J. 2010 Jun;22(2):49-56.

14.

Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Bazzoli C, Bénech H, Rey E, Retout S, Salmon D, Duval X, Tréluyer JM, Mentré F; COPHAR2-ANRS 111 Study Group.

Antimicrob Agents Chemother. 2011 Jul;55(7):3423-31. doi: 10.1128/AAC.01487-10. Epub 2011 May 16.

15.

Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV.

J Clin Pharmacol. 2011 Dec;51(12):1665-73. doi: 10.1177/0091270010388650. Epub 2011 Jan 13.

16.

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM.

J Antimicrob Chemother. 2011 Feb;66(2):240-50. doi: 10.1093/jac/dkq447. Epub 2010 Nov 30. Review.

17.

Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Paintsil E, Dutschman GE, Hu R, Grill SP, Wang CJ, Lam W, Li FY, Ghebremichael M, Northrup V, Cheng YC.

Antimicrob Agents Chemother. 2011 Feb;55(2):895-903. doi: 10.1128/AAC.01303-10. Epub 2010 Nov 15.

18.

Zidovudine and Lamivudine for HIV Infection.

Anderson PL, Rower JE.

Clin Med Rev Ther. 2010;2:a2004.

19.

Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.

Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):170-5. doi: 10.1097/QAI.0b013e3181e36420.

20.

Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.

Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, Court MH.

J Clin Pharmacol. 2009 Sep;49(9):1079-90. doi: 10.1177/0091270009338482. Epub 2009 Jul 23.

Supplemental Content

Support Center